Adolescents with atopic dermatitis experience a higher prevalence and a higher frequency of bullying compared with their peers who do not have atopic dermatitis, according to the results of a new ...

Adolescents with AD have reported appearance-based bullying. To evaluate the association between AD and the prevalence and frequency of bullying, researchers analyzed cross-sectional data from adult ...

Elaine Siegfried, MD: We don’t really use the terms acute, subacute, and chronic when we’re talking about atopic dermatitis. There’s just not a clinical correlation to classifying it that way. Maybe ...

Children and adolescents with atopic dermatitis (AD) tended to have a higher number of delinquent behaviors than those without AD, including fighting, cheating on exams, and suspension. Incidence of ...

Please provide your email address to receive an email when new articles are posted on . MIAMI BEACH, Fla. — Social media may contribute to the high rates of mental health problems and disorders among ...

Findings seen through 76 weeks of treatment for adolescents taking 15- or 30mg doses for moderate to severe atopic dermatitis. HealthDay News — Long-term treatment of adolescents with moderate to ...

Please provide your email address to receive an email when new articles are posted on . Tralokinumab significantly improved atopic dermatitis in adolescents, according to phase 3 trial results ...

BALLERUP, Denmark & MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced 16-week results of a 52-week monotherapy trial showing tralokinumab ...

Lebrikizumab is an interleukin-13 antagonist approved as Ebglyss for the treatment of adults and pediatric patients with moderate to severe atopic dermatitis.

MedPage Today has been reporting on a variety of subjects relating to atopic dermatitis, especially regarding the adolescent and pediatric population. Answer these questions to see how much you’ve ...

Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib is safe and effective through 76 weeks, according to a study published online Oct. 23 in JAMA ...